NCPC(SH:600812) Sou Hu Cai Jing·2025-08-13 08:53Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of North China Pharmaceutical Co., Ltd. as of August 13, 2025, indicating a stock price of 6.9 yuan, a slight increase of 0.29%, and a trading volume of 602,000 hands with a transaction amount of 415 million yuan [1] - The company reported total revenue of 2.574 billion yuan for Q1 2025, reflecting a year-on-year growth of 0.65%, while net profit attributable to shareholders reached 57.49 million yuan, showing a significant increase of 216.72% [1] - The company has a current ratio of 0.731, a quick ratio of 0.532, and a debt-to-asset ratio of 69.30%, indicating its liquidity and financial leverage status [1] Group 2 - North China Pharmaceutical has made investments in 45 enterprises and participated in 5,000 bidding projects, showcasing its active engagement in the market [2] - The company holds 642 trademark registrations and 139 patents, along with 349 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]